LymphomaArchives
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma
Lymphoma 1 min.
CD19-directed chimeric antigen receptor (CAR) T-cell (CAR T) therapy is a well-established treatment for B-cell malignancies, but accessibility, toxicities, lack of persistence, modest anti-tumor activity, restricted trafficking and tumor antigen escape are among its limitations.1 Concern for excessive...
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Lymphoma 1 min.
Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard-of-care therapy with frontline DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, rituximab). However, treatment strategies following relapse after DA-EPOCH-R...
CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma
Lymphoma 1 min.
CD47 is an immune checkpoint molecule widely expressed on various cell types and has emerged as a key target in cancer immunotherapy due to its role in mediating tumor immune escape viathe ‘don't eat me' signal. In lymphoma, CD47 expression shows heterogeneity across subtypes, with elevated...
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma
Lymphoma 1 min.
We conducted a retrospective, multi-center, real-world study to evaluate efficacy and safety of zanubrutinib combination therapy as first-line treatment for diffuse large B-cell lymphoma (DLBCL) between August 2020 and August 2025. Patients received RCHOP as standard therapy, while those with central...
